# Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor

> **NCT00523809** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 5 (actual)

## Conditions studied

- Breast Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** Bevacizumab
- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **DRUG:** Fludarabine
- **DRUG:** Melphalan
- **DRUG:** Thymoglobulin

## Key facts

- **NCT ID:** NCT00523809
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Slow accrual.
- **Last updated:** 2013-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00523809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00523809, "Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00523809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*